Musculoskeletal Pain is an indication for drug development with over 50 pipeline drugs currently active. According to GlobalData, preregistered drugs for Musculoskeletal Pain have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Musculoskeletal Pain compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Musculoskeletal Pain overview

Musculoskeletal pain refers to discomfort or pain affecting the bones, muscles, ligaments, tendons, and nerves in the body. It commonly arises from injuries, overuse, poor posture, or underlying medical conditions like arthritis or fibromyalgia. Symptoms can vary widely, encompassing dull aches, sharp pains, stiffness, or limited mobility in affected areas. Diagnosis involves medical history assessment, physical examinations, and sometimes imaging tests. Treatment approaches often combine pain management techniques such as rest, physical therapy, medications, and in severe cases, surgery. Lifestyle modifications like exercise, ergonomic adjustments, and proper body mechanics are also crucial in managing musculoskeletal pain for improved quality of life.

For a complete picture of PTSR and LoA scores for drugs in Musculoskeletal Pain, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.